MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2023 International Congress

    Apomorphine sublingual film for OFF episodes in PD: Impact on orthostatic hypotension during dose-optimization

    W. Jost, M. Coelho, M. Fonseca, G. Castilla-Fernández, D. Magalhães, CK. Denecke Muhr (Wolfach, Germany)

    Objective: To assess the occurrence of orthostatic hypotension (OH) during apomorphine sublingual film (SL-APO) dose-optimization in patients with Parkinson’s disease (PwPD). Background: SL-APO has been…
  • 2023 International Congress

    Apomorphine effects on Parkinson’s disease fluctuation related pain: a pilot study

    P. Alizadeh, V. Bruno, K. Naser, A. Abusarair, B. Achen (Calgary, Canada)

    Objective: To evaluate the effect and safety of subcutaneous apomorphine as a treatment for fluctuation-related pain in Parkinson's disease (PD). Background: Pain is one of…
  • 2023 International Congress

    VALIdation of models for assessing eligibility for referral for Device-Aided Treatment in Parkinson’s disease (VALIDATE)

    H. Moes, E. Buskens, A. Portman, B. van Harten, M. van Kesteren, T. Mondria, L. Teune, E. van Wensen, M. van Onna, M. Schilperoord, A. Wertenbroek, M. Tjepkema-Cloostermans, L. Dorresteijn, T. van Laar (Groningen, Netherlands)

    Objective: To externally validate the Dutch Device-Aided Therapy Screening tool (D-DATS) and to compare it with the 5-2-1 criteria. Background: Timely identification of patients with…
  • 2023 International Congress

    Early onset of efficacy during titration in US phase 3 open-label InfusON trial of apomorphine subcutaneous infusion for Parkinson’s disease motor fluctuations

    S. Isaacson, G. Ceresoli-Borroni, A. Espay, R. Pahwa, P. Agarwal, H. Shill, J. Hui, K. Dashtipour, M. Lew, P. Qin, P. Lewitt (Boca Raton, USA)

    Objective: Evaluate safety/onset of efficacy during titration of continuous subcutaneous apomorphine infusion (CSAI) for motor fluctuations in U.S. outpatients with Parkinson’s disease (PD). Background: Global…
  • 2023 International Congress

    Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain

    I. Muro Garcia, J. Alonso Maroto, B. Gonzalez Garcia, E. Carabajal Pendon, E. Casas, L. Lopez Manzanares (Madrid, Spain)

    Objective: To determine the number of patients that maintain infusion therapies (continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel (LCIG)) as treatment for advanced…
  • 2023 International Congress

    The effect of continuous subcutaneous apomorphine infusion on vitamin B metabolites and plasma homocysteine in Parkinson’s disease patients

    O. Phokaewvarangkul, N. Kantachadvanich, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To evaluate the plasma level of vitamin B and homocysteine between PD patients with conventional medications and PD patients with CSAI. Background: Although levodopa…
  • 2022 International Congress

    Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Incremental Motor Improvement Observed with Increasing Doses

    S. Isaacson, I. Zhang, E. Pappert, A. Bowling (Boca Raton, USA)

    Objective: Evaluate magnitude of motor improvement with increasing doses of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease (PD) and OFF episodes. Background: Identifying…
  • 2022 International Congress

    Use of apomorphine infusion pump in the elderly population : a 5 years follw up study on efficacy, safety and tolerability in a cohort bases study

    C. Borrue- Fernandez, M. Mata, C. Jimeno, M. Almarcha (San Sebastian Reyes, Spain)

    Objective: Evaluate the efficacy, tolerability and safety of subcutaneous apomorphine infusion in elderly patients with advanced Parkinson's disease in a five years follow up cohort. Background: Continuous infusion by subcutaneous apomorphine pump has…
  • 2022 International Congress

    May apomorphine be helpful for the axial symptoms of Parkinson’s Disease?

    A. Alonso-Canovas, P. Perez Torre, G. Sanchez Diez, A. Patiño Paton, N. Gonzalez, I. Parees Moreno, JC. Martinez Castrillo (Madrid, Spain)

    Objective: To assess the effect of continuous subcutaneous infusion of apomorphine on axial symptoms of Parkinson Disease. Background: Axial symptoms of Parkinson’s Disease may be…
  • 2022 International Congress

    Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24475 (not found)
  • An atypical and interesting feature of Parkinson´s disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley